Avisi

Executive Summary

Avisi Technologies Inc. is a private, clinical-stage medical device company based in San Diego, CA, pioneering a nanotechnology-enabled implant called VisiPlate for the treatment of open-angle glaucoma. The VisiPlate is an ultrathin, multichannel aqueous shunt designed to lower intraocular pressure (IOP) with a minimally invasive approach. By leveraging advanced micro-fabrication techniques, Avisi aims to improve patient comfort and reduce the risk of scarring compared to traditional glaucoma drainage devices. Founded in 2019, the company is at an early stage of development, with no approved products or revenues to date. Its technology represents a novel approach in the glaucoma treatment landscape, potentially offering a safer and more effective option for millions of patients worldwide. Avisi is positioned to address the significant unmet need for long-term IOP control with fewer complications, positioning itself as a promising player in the ophthalmic medical device market.

Upcoming Catalysts (preview)

• Q1 2027Completion of first-in-human clinical trial for VisiPlate70% success
• Q2 2026FDA Breakthrough Device Designation or IDE approval60% success
• Q3 2026Series A or B financing round to fund pivotal studies80% success